Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Key Highlights
- ➤Vanda (VNDA) Phase III VQW-765 study missed its primary endpoint in social anxiety disorder
- ➤546 adults were randomized in Study 3201 across approximately 30 U.S. clinical sites
- ➤VQW-765 showed no significant benefit versus placebo in female participants, P=0.8899
- ➤Full-population key secondary endpoint also missed, with P=0.6605
- ➤VQW-765 program is on hold pending further analysis of the full dataset
Expert Statements
Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals
“We are disappointed that Study 3201 did not confirm the earlier Phase II findings2 for VQW-765 in patients with social anxiety disorder,”
Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals
“We thank the participants, investigators and site staff who made this study possible.”
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program PR Newswire
* Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint * Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety disorder, did not meet its primary endpoint.
Get started
Create a free account to read the full story.